Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
Weller J, Schäfer N, Schaub C, Potthoff AL, Steinbach JP, Schlegel U, Sabel M, Hau P, Seidel C, Krex D, Goldbrunner R, Pietsch T, Tzaridis T, Zeyen T, Borger V, Güresir E, Vatter H, Herrlinger U, Schneider M. Weller J, et al. Among authors: schaub c. J Neurooncol. 2022 Aug;159(1):95-101. doi: 10.1007/s11060-022-04046-z. Epub 2022 Jun 15. J Neurooncol. 2022. PMID: 35704157 Free PMC article. Clinical Trial.
Vemurafenib for leptomeningeal melanomatosis.
Schäfer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkämper C, Mack F, Niehusmann P, Simon M, Greschus S, Kuchelmeister K, Herrlinger U, Glas M. Schäfer N, et al. Among authors: schaub c. J Clin Oncol. 2013 Apr 10;31(11):e173-4. doi: 10.1200/JCO.2012.46.5773. Epub 2013 Mar 4. J Clin Oncol. 2013. PMID: 23460716 No abstract available.
18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.
Kebir S, Gaertner FC, Mueller M, Nelles M, Simon M, Schäfer N, Stuplich M, Schaub C, Niessen M, Mack F, Bundschuh R, Greschus S, Essler M, Glas M, Herrlinger U. Kebir S, et al. Among authors: schaub c. Oncol Lett. 2016 Mar;11(3):2195-2198. doi: 10.3892/ol.2016.4189. Epub 2016 Feb 4. Oncol Lett. 2016. PMID: 26998148 Free PMC article.
Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.
Schäfer N, Gielen GH, Kebir S, Wieland A, Till A, Mack F, Schaub C, Tzaridis T, Reinartz R, Niessen M, Fimmers R, Simon M, Coch C, Fuhrmann C, Herrlinger U, Scheffler B, Glas M. Schäfer N, et al. Among authors: schaub c. J Cancer Res Clin Oncol. 2016 Jul;142(7):1581-9. doi: 10.1007/s00432-016-2161-0. Epub 2016 Apr 21. J Cancer Res Clin Oncol. 2016. PMID: 27100354 Clinical Trial.
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O. Schaub C, et al. J Neurooncol. 2016 Aug;129(1):93-100. doi: 10.1007/s11060-016-2144-7. Epub 2016 May 18. J Neurooncol. 2016. PMID: 27193554
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Schäfer N, et al. Among authors: schaub c. Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204. Neuro Oncol. 2018. PMID: 29121274 Free PMC article. Clinical Trial.
183 results